[go: up one dir, main page]

CN1267219A - 抑制脑神经血管性疾病和肌性头痛的组合物,成套释药器具及其方法, - Google Patents

抑制脑神经血管性疾病和肌性头痛的组合物,成套释药器具及其方法, Download PDF

Info

Publication number
CN1267219A
CN1267219A CN98808214A CN98808214A CN1267219A CN 1267219 A CN1267219 A CN 1267219A CN 98808214 A CN98808214 A CN 98808214A CN 98808214 A CN98808214 A CN 98808214A CN 1267219 A CN1267219 A CN 1267219A
Authority
CN
China
Prior art keywords
headache
patient
medicine
compositions
local anaesthetics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98808214A
Other languages
English (en)
Chinese (zh)
Inventor
布鲁斯·H·勒文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bruce H. Levin
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra AB filed Critical Astra AB
Publication of CN1267219A publication Critical patent/CN1267219A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN98808214A 1997-07-21 1998-07-17 抑制脑神经血管性疾病和肌性头痛的组合物,成套释药器具及其方法, Pending CN1267219A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US89719297A 1997-07-21 1997-07-21
US08/897,192 1997-07-21
US7284598P 1998-01-28 1998-01-28
US60/072,845 1998-01-28
US8455998P 1998-05-06 1998-05-06
US60/084,559 1998-05-06

Publications (1)

Publication Number Publication Date
CN1267219A true CN1267219A (zh) 2000-09-20

Family

ID=27372174

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98808214A Pending CN1267219A (zh) 1997-07-21 1998-07-17 抑制脑神经血管性疾病和肌性头痛的组合物,成套释药器具及其方法,

Country Status (20)

Country Link
EP (1) EP0999839B1 (is)
JP (1) JP4521117B2 (is)
KR (1) KR20010022041A (is)
CN (1) CN1267219A (is)
AR (1) AR013240A1 (is)
AT (1) ATE269702T1 (is)
AU (1) AU8574398A (is)
BR (1) BR9810773A (is)
CA (1) CA2297097C (is)
DE (1) DE69824730T2 (is)
EE (1) EE200000050A (is)
HU (1) HUP0003953A3 (is)
ID (1) ID24903A (is)
IL (2) IL134087A0 (is)
IS (1) IS5349A (is)
NO (1) NO20000293L (is)
PL (1) PL338176A1 (is)
SK (1) SK187899A3 (is)
TR (1) TR200000149T2 (is)
WO (1) WO1999003473A1 (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704349D0 (en) * 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
JP4632499B2 (ja) * 1999-08-26 2011-02-16 武田薬品工業株式会社 鼻粘膜付着マトリックス
WO2001043733A2 (en) * 1999-12-15 2001-06-21 Levin Bruce H Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
GB9930083D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US7146209B2 (en) 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
US7117033B2 (en) 2000-05-08 2006-10-03 Brainsgate, Ltd. Stimulation for acute conditions
US6853858B2 (en) 2000-05-08 2005-02-08 Brainsgate, Ltd. Administration of anti-inflammatory drugs into the central nervous system
AU5662001A (en) 2000-05-08 2001-11-20 Brainsgate Ltd. Method and apparatus for stimulating the sphenopalatine ganglion to modify properties of the bbb and cerebral blood flow
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US7636597B2 (en) 2002-11-14 2009-12-22 Brainsgate, Ltd. Surgical tools and techniques for stimulation
US7561919B2 (en) 2002-11-14 2009-07-14 Brainsgate Ltd. SPG stimulation via the greater palatine canal
WO2005062829A2 (en) 2003-12-19 2005-07-14 Advanced Bionics Corporation Skull-mounted electrical stimulation system and method for treating patients
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
ATE529133T1 (de) * 2004-08-18 2011-11-15 Medrx Co Ltd Topisches präparat
KR101367479B1 (ko) * 2008-07-21 2014-03-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 귀 질병 치료를 위한 제어 방출형 항미생물성 조성물 및 방법
DE102008037682A1 (de) 2008-08-14 2010-04-08 Strackharn, Klaus, Dr.med. Verwendung äquipotenter Dosierungen von Lokalanästetika oder Derivaten davon zur Therapie chronischer Schmerzen
US9889109B2 (en) 2012-09-28 2018-02-13 St. Renatus, Llc Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
CN103432378A (zh) * 2013-08-15 2013-12-11 吕清华 一种治疗神经血管性头痛的中药
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
EP3093043B1 (en) 2015-05-13 2018-11-14 Brainsgate Ltd. Implant and delivery system for neural stimulator
EA202191506A1 (ru) * 2018-12-19 2021-10-08 Нортик Холдингз Инк. Терапевтическая композиция интраназального лидокаина
WO2020152212A1 (en) * 2019-01-22 2020-07-30 Icm (Institut Du Cerveau Et De La Moelle Épinière) Local anesthetic for the treatment of neurological symptoms resulting from brain dysfunctions
GB2628149A (en) * 2023-03-16 2024-09-18 Lee Nathaniel Wurie Nasal spray for performing sphenopalatine ganglion block

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321061D0 (en) * 1993-10-13 1993-12-01 Chiroscience Ltd Analgestic agent and its use
DE19524691A1 (de) * 1995-07-06 1997-01-09 Liedtke Pharmed Gmbh Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen
DE19526019A1 (de) * 1995-07-17 1997-01-23 Liedtke Pharmed Gmbh Methode und Zusammensetzung einer topischen Therapie von Kopfschmerzen
BE1009851A3 (fr) * 1996-01-11 1997-10-07 Thiebauld Charles Marie Composition pharmaceutique pour le traitement des cephalees et son utilisation.
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9704349D0 (en) * 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use

Also Published As

Publication number Publication date
KR20010022041A (ko) 2001-03-15
EE200000050A (et) 2000-10-16
IS5349A (is) 2000-01-18
ID24903A (id) 2000-08-31
IL134087A0 (en) 2001-04-30
JP2001513483A (ja) 2001-09-04
SK187899A3 (en) 2000-12-11
IL134087A (en) 2006-10-31
ATE269702T1 (de) 2004-07-15
NO20000293D0 (no) 2000-01-20
JP4521117B2 (ja) 2010-08-11
NO20000293L (no) 2000-03-20
CA2297097A1 (en) 1999-01-28
EP0999839B1 (en) 2004-06-23
DE69824730D1 (de) 2004-07-29
AU8574398A (en) 1999-02-10
HUP0003953A3 (en) 2002-02-28
BR9810773A (pt) 2000-09-19
AR013240A1 (es) 2000-12-13
WO1999003473A1 (en) 1999-01-28
PL338176A1 (en) 2000-10-09
TR200000149T2 (tr) 2000-05-22
EP0999839A1 (en) 2000-05-17
HUP0003953A1 (hu) 2002-01-28
DE69824730T2 (de) 2005-07-14
CA2297097C (en) 2009-04-07

Similar Documents

Publication Publication Date Title
CN1267219A (zh) 抑制脑神经血管性疾病和肌性头痛的组合物,成套释药器具及其方法,
US6432986B2 (en) Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US20220152394A1 (en) Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve
US6491940B1 (en) Apparatus for administering composition for inhibiting cerebral neurovascular disorders and muscular headaches
US9302096B2 (en) Apparatus for treating cerebral neurovascular disorders including headaches by neural stimulation
US20160030408A1 (en) Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve
US20010004644A1 (en) Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
ES2290741T3 (es) Metodo de tratamiento de trastornos del tracto urinario inferior.
RU2557533C2 (ru) Способы лечения синдрома фибромиалгии
ES2275229T3 (es) Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
AU723047B2 (en) Deprenyl compounds for treatment of glaucoma
KR101461567B1 (ko) 약물 중독 치료 및 중독 관련 행동의 개선을 위한 조성물
US20050281751A1 (en) Directed intranasal administration of pharmaceutical agents
US8658683B2 (en) Combination of alpha-2 receptor agonist (clonidin) and anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
TW200401649A (en) Methods and compositions using cholinesterase inhibitors
JP2013515002A (ja) 三叉神経・自律神経性頭痛、片頭痛、および血管症状の治療および予防のための方法および組成物
WO2001043733A2 (en) Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
US20250275924A1 (en) Anticholinergic Agents and Muscarinic Agonists for the Treatment of Demodex Related Conditions
JP2008523097A (ja) Ｄ−トレオメチルフェニデートを用いた治療
MXPA00000705A (en) Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
CZ2000215A3 (cs) Kompozice, kity a způsoby pro inhibici cerebrálních neurovaskuiárních poruch a svalové bolestí hlavy
HK1176285B (en) Compositions for treating drug addiction and improving addiction-related behavior

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BRUCE H. LEVIN

Free format text: FORMER OWNER: ASTRAZENCA AB

Effective date: 20030121

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20030121

Address after: Pennsylvania

Applicant after: Bruce H. Levin

Address before: Swedish Sodertalje

Applicant before: Astra Zeneca Aktiebolag

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication